Medscape: Recombinant IFN plus antivirals may boost COVID-19 recovery versus traditional IFN
UC expert points out weaknesses in the research
Reuters Health, as reported by Medscape, published a story on research out of China showing that in patients with moderate to severe COVID-19, recombinant super-compound interferon (rSIFN-co) plus baseline antivirals was associated with a shorter time to clinical improvement than the same regimen using traditional interferon-alpha. Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was one of the experts who reacted to the study.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
"The study shows a minimal benefit to the re-engineered version of interferon alfa. If you look at 28 days, no difference," Fichtenbaum says. "So, it was really a minor difference at days seven and 14. If you look closely at the article, by the 'ordinal scale' that most researchers use, no difference was seen. No data was presented on virologic response."
He added that more information is needed to validate the findings.
"We need a lot more data and proof before I would use this," he says. "And the lack of a control group that got just standard of care is a big weakness of this study."
Lead image/Colleen Kelley/UC Creative + Brand
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
Local 12: Head injury survivor, doctor share importance of...
April 23, 2024
Local 12 spoke with patient Shane Shapiro and the University of Cincinnati's Laura Ngwenya about the importance of wearing a helmet following Shapiro's traumatic brain injury and recovery.
WVXU: Why is part of Green Township called Dent?
April 23, 2024
UC College of Arts and Sciences professor tells WVXU that Ohio's glacial past might explain how Dent got its name.
WVXU: Find your CPAP annoying? UC researchers are working on a...
April 22, 2024
Dr. Liran Oren is leading a research team at the University of Cincinnati developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.